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Abstract 
BACKGROUND: Vaspin concentration was thought to be associated with obesity, impaired insulin sensitivity, and 
fitness level. The correlation of vaspin and leptin supports the theory of vaspin associated with body fat mass. 
AIM: To determine the correlation between visceral fat distributions and serum vaspin level in type II DM patients. 
METHODS: We conduct an observational, analytical cross-sectional study. Sixty subjects with type II diabetes 
mellitus who came to Diabetes Center of Sanglah General Hospital were included consecutively. Each subject 
has to sign an informed consent before physical and laboratory examination took place. Spearman correlation test 
was used to analyse the correlation between waist circumference and visceral fat percentage with serum vaspin 
level since the data were not distributed normally. 
RESULTS: Mean laboratory results in all subjects of vaspin levels was 2.389 ± 3.586 ng/ml, mean waist 
circumference was 94.95 ± 11.78 cm and mean visceral fat percentage was 18.05 ± 23.63%. We found we found 
no significant correlation between between vaspin with waist circumference (r = -0.044; p = 0.738) and visceral fat 
percentage (r = -0.103; p = 0.435). 
CONCLUSIONS: The vaspin level did not significantly correlate with waist circumference and visceral fat 
percentage in type II diabetes patients. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Diabetes mellitus (DM) is one of medical and 
social health problems both in developed and 
developing countries. The prevalence is increasing, 
and approximately 4% of the world population 
suffered from DM. This disease is closely related to 
obesity and endocrinal activity of adipose tissue [1]. 
The association between the increase of body 
weight and waist-hip ratio (WHR) with the incidence of 
impaired glucose tolerance, dyslipidemia (primarily 
hypertriglyceridemia) and hypertension firstly reported 
in detail at various population-based studies in the 
early 1980s. The combination of symptoms, which are 
known as metabolic syndrome, is reported as a major 
cause of the global epidemic and death caused by DM 
and cardiovascular disease. However, those studies 
have not comprehensively described the involvement 
of adipose tissue with glucose metabolism [1], [2], [3]. 
The visceral fat tissue is not only involved as 
fat-storage but also as an active endocrine organ, in 
which the occurrence of obesity is causing 
hyperplastic changes in this tissue [3].
 
Vaspin (visceral 
adipose tissue-derived serine protease inhibitor) is the 
most recent adipocytokine exclusively expressed by 
rat visceral fat tissue, which is Otsuka Long-Evans 
Tokushima Fatty (OLETF), an experimental animal 
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model for obesity and types II DM. Vaspin is a family 
of serine protease inhibitor. In human, the expression 
of vaspin found in adipose, gaster, liver and 
pancreatic tissue. Vaspin also found at the 
hypothalamus of db/db and C57BL/6 mouse [4]. 
The increase of serum vaspin concentration 
associated with obesity, impaired insulin sensitivity, 
and fitness level, and insulin resistance. Serum vaspin 
also significantly correlated with leptin, thus support 
the theory that vaspin associated with body fat mass. 
However, other studies found no association between 
serum vaspin with insulin sensitivity or obesity 
parameters and fat distribution. In one study, serum 
vaspin levels significantly correlated with fasting 
insulin, HOMA-IR and ratio of visceral and 
subcutaneous vaspin expression however, if 
compared to obese patients with sensitive insulin and 
resistance after matching with BMI, age and gender, 
no significant difference of vaspin levels were found in 
both groups. This suggests that the association 
between serum vaspin levels, fat distribution and 
insulin sensitivity is far more complex than expected 
[5]. 
According to the data above, to date, the 
association between the distribution of visceral fat with 
vaspin serum remains a controversy and their 
association in type II DM patients remain unclear, 
hence a study to determine the correlation between 
visceral fat distribution (measured with waist 
circumference and visceral fat percentage) with serum 
vaspin level in type II DM patients is needed. 
 
 
Methods 
 
This was an observational, analytical cross-
sectional study. This study was approved by the 
Ethics Commission for Research at Medical Faculty of 
Udayana University, Denpasar Bali. The subjects 
were 60 type II diabetes mellitus patients who came to 
Diabetes Center of Sanglah General Hospital, 
Denpasar Bali. Samples were taken consecutively 
based on the order of the patients which came to 
Diabetes Center until minimal sample required 
achieved. 
Table 1: Characteristic of Subjects 
No Variables Mean Standard deviation Unit 
1 Vaspin 2.389 3.586 ng/ml 
2 Waist circumference 94.95 11.78 Cm 
3 Visceral fat percentage 18.05 23.63 % 
 
Each subject was asked to sign an informed 
consent. The identity of the patients was recorded and 
followed by physical examination and laboratory 
examination. History of diabetes, duration of having 
diabetes, medication history (including diabetic drugs) 
were asked — physical examination including vital 
signs, abdominal circumference and visceral fat 
percentage measurement with bioelectric impedance. 
Blood samples then collected to measure serum 
vaspin concentration, performed with 
“Human/Mouse/rat SERPINA12/Vaspin (Competitive 
EIA) kit” from Life Span Bio Sciences, Inc. Spearman 
correlation test was used to analyse the correlation 
between waist circumference and visceral fat 
percentage with serum vaspin level since the data 
were not distributed normally. 
 
 
Results 
 
Mean vaspin levels in all subjects was 2.389 ± 
3.586 ng/ml, mean waist circumference in all subjects 
was 94.95 ± 11.78 cm and mean visceral fat 
percentage was 18.05 ± 23.63%.  
Table 2: Correlation of Vaspin with Waist Circumference and 
Visceral Fat Percentage 
No Variables R P 
1 Waist circumference -0.044 0.738 
2 Visceral fat circumference -0.103 0.435 
 
No significant correlation was found between 
vaspin with waist circumference (r = -0.044; p = 0.738) 
and visceral fat percentage (r = -0.103; p = 0.435). 
 
 
Figure 1: Scatter Plot Correlation between Waist Circumference and 
Serum Vaspin (left); Scatter Plot Correlation between Visceral Fat 
Percentage and Vaspin Levels (right) 
 
 
Discussion 
 
Vaspin (visceral adipose tissue-derived serine 
protease inhibitor) is the most recent adipocytokine 
exclusively expressed by visceral fat tissue of Otsuka 
Long-Evans Tokushima Fatty (OLETF) mouse, an 
experimental animal model for obesity and type II DM. 
Vaspin is a family of serine protease inhibitor. Serum 
vaspin concentration decreases significantly along 
with an increase in age and severe hyperglycemic 
condition. This process could reduce with insulin 
therapy or pioglitazone in human, the expression of 
vaspin found in adipose tissue, gaster, liver, and 
pancreas. The expression of vaccine also found at the 
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hypothalamus of db/db and C57BL/6 mouse. The 
administration of vaspin recombinant on the obese 
mouse may improve the glucose tolerance and 
increase insulin sensitivity by affecting the expression 
of gene candidate for insulin resistance and rapidly 
decrease food intake [4]. 
The exact mechanism on how vaspin 
associated with worsening of glucose homeostasis 
and insulin sensitivity remains unclear. Based on 
existing data regarding vaspin mechanism of action, it 
has been suggested that vaspin inhibit proteases 
which involved in hormone or molecule degradation 
which decreased glucose either direct or indirect — 
the increase of serum vaspin levels associated with 
obesity, impairment in insulin sensitivity and fitness 
level. Serum vaspin also significantly correlated with 
body fat mass. In a female with polycystic ovary 
syndrome and insulin resistance, the administration of 
metformin may decrease serum vaspin levels and 
improve insulin sensitivity. 
The result of the current study obtained that 
mean vaspin levels was 2.389 ± 3.586 ng/ml. This 
result was higher compared to other studies in Asia. 
One study in Bangladesh found that mean levels of 
serum vaspin was 0.83 ± 0.28 ng/ml, while a study in 
Turkey and China found 0.18 ± 0.10 ng/ml and 0.69 ± 
0.31 ng/ml, respectively. These shows that vaspin 
levels differ in various populations [5]. 
This study obtained no significant correlation 
of vaspin with parameters of adipose tissue, e.g., 
waist circumference can visceral fat percentage. The 
correlation between vaspin and parameters of adipose 
tissue remain controversial. Some research found no 
association between serum vaspin with insulin 
sensitivity or parameters of obesity and fat 
distribution. In one study, serum vaspin levels 
significantly correlated with fasting insulin, HOMA-IR 
and ratio of visceral and subcutan vaspin expression. 
However, if compared to insulin-sensitive and insulin-
resistance obese patients after matching with BMI, 
age, and gender, no significant difference was found 
in both groups. This suggests that the association 
between serum vaspin levels, fat distribution and 
insulin sensitivity is far more complex than imagined 
[5]. 
The different result was also affected by the 
type of adipose tissue which produces vaspin. The 
expression of vaspin mRNA detected at visceral and 
subcutan adipose tissue. Visceral vaspin mRNA 
correlated with body mass index, body fat percentage, 
and plasma glucose levels 2 hours after an oral 
glucose tolerance test, but not correlated with waist 
circumference or waist-hip ratio. While subcutaneous 
vaspin mRNA correlated with the waist-hip ratio, 
fasting insulin plasma concentration, and glucose 
delivery. But linear regression analysis showed body 
fat percentage as the most powerful predictor of 
visceral vaspin, while insulin sensitivity as the most 
powerful predictor for subcutaneous vaspin [6]. 
Visceral and subcutan vaspin were not distinguished 
in the current study. Thus the relationship between 
both with adipose tissue parameters could not be 
depicted through this study. 
In conclusion, vaspin did not significantly 
correlate with waist circumference and visceral fat 
percentage in diabetes patients. Further study with 
more samples to determine characteristics of vaspin 
in various ethnicity and race is needed and 
differentiate the subcutaneous, and visceral vaspin is 
needed. 
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